Steven Leonard Chapman Sells 1,709 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 1,709 shares of the company’s stock in a transaction on Monday, October 21st. The shares were sold at an average price of $120.76, for a total value of $206,378.84. Following the sale, the chief executive officer now owns 194,615 shares of the company’s stock, valued at approximately $23,501,707.40. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Steven Leonard Chapman also recently made the following trade(s):

• On Tuesday, October 15th, Steven Leonard Chapman sold 4,523 shares of Natera stock. The shares were sold at an average price of $130.40, for a total value of $589,799.20.
• On Monday, September 16th, Steven Leonard Chapman sold 5,024 shares of Natera stock. The stock was sold at an average price of $128.48, for a total transaction of $645,483.52.
• On Thursday, August 15th, Steven Leonard Chapman sold 5,583 shares of Natera stock. The shares were sold at an average price of $118.91, for a total transaction of $663,874.53.
• On Monday, July 29th, Steven Leonard Chapman sold 4,084 shares of Natera stock. The stock was sold at an average price of $102.77, for a total value of $419,712.68.

Natera Price Performance

NASDAQ:NTRA opened at $118.65 on Thursday. The firm has a market capitalization of $14.57 billion, a price-to-earnings ratio of -38.03 and a beta of 1.53. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01. The business has a 50 day simple moving average of $123.43 and a 200-day simple moving average of $111.03. Natera, Inc. has a 1 year low of $36.90 and a 1 year high of $133.54.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.39. The business had revenue of $413.35 million for the quarter, compared to analysts’ expectations of $343.00 million. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The business’s revenue was up 58.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.97) earnings per share. Equities analysts forecast that Natera, Inc. will post -1.96 EPS for the current year.

Institutional Trading of Natera

Institutional investors have recently added to or reduced their stakes in the company. Itau Unibanco Holding S.A. purchased a new stake in shares of Natera in the second quarter worth approximately $28,000. Quarry LP lifted its position in shares of Natera by 148.4% during the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after purchasing an additional 190 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Natera by 50.0% during the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 108 shares during the period. Tobam bought a new position in shares of Natera in the second quarter worth about $74,000. Finally, DekaBank Deutsche Girozentrale purchased a new position in Natera in the 1st quarter worth about $83,000. Institutional investors own 99.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on NTRA shares. Canaccord Genuity Group upped their price target on Natera from $130.00 to $145.00 and gave the stock a “buy” rating in a research report on Tuesday, August 27th. Piper Sandler reaffirmed an “overweight” rating and set a $150.00 price target on shares of Natera in a report on Friday, September 13th. TD Cowen upped their price target on shares of Natera from $137.00 to $145.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. BTIG Research lifted their target price on shares of Natera from $125.00 to $135.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Finally, Robert W. Baird increased their price target on Natera from $117.00 to $120.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat.com, Natera has an average rating of “Moderate Buy” and an average price target of $124.44.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.